Note: Descriptions are shown in the official language in which they were submitted.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
COMPOSITIONS AND METHODS
FOR THE TREATMENT OF PARHINSON'S DISEASE
BACKGROUND
Idiopathic Parkinson's Disease (IPD) is a progressive neurodegenerative
disorder. The onset of IPD symptoms begin to manifest when a threshold
reduction of
60%-70% nigral neurons accompanied by an 80%-90% attenuation in striatal
dopamine
efflux, has been reached (Koller, W.C., "When does Parkinson's disease
begin?",
(1992) Neurology 42(S4):27-31). Symptoms include tremor, postural imbalance,
rigidity, bradykinesia and akinesia (Diagnostic Clinical Neuropsychology,
Bigler, E.
and Clement, P., Eds., 3rd Ed. 1997). These symptoms intensify as the disease
progresses. In severe stages of IPD, following the onset of akinesia, even the
simplest
movements require a monumental degree of concentration and mental effort,
often to
the point of anguish (Textbook of Medical Physiolo~y, Guyton, A.C. and Hall,
J.E.,
Eds., 9t'' Ed., W.B. Saunders Company, Philadelphia, PA, 1996). IPD is also
characterized by a number of autonomic (Vainshtok, A.B., "Treatment of
Parkinsonism
with delagil," (1972) Klin. Med (Mosk) 50(9):51-56) and non-motor symptoms
including depression (Cummings, J.L., "Depression and Parkinson's Disease: A
Review," (1992) Am. J. Psychiatry 149(4):443-454) and frontal lobe dysfunction
(Gotham, A.M. et al., "Levodopa treatment may benefit or impair'frontal'
function in
Parkinson's disease," (1986) Lancet 25;2(8513):970-971).
In the United States, it is estimated that 5-24 in every 100,000 people suffer
from IPD, with the majority of low income cases going undiagnosed
(Chrischilles, E.A.
et al., "The health burdens of Parkinson's disease," (1998) Movement Disorders
13(3):406-413 ). In 1995, the World Health Organization conducted a global
epidemiological evaluation of the incidence of IPD, showing a worldwide
incidence of
5.32 per 100,000 people with an astounding incidence rate of 49.33 per 100,000
people
over the age of 65 (M. Privett, WHO). Although more recent epidemiological
figures
are unavailable, in 1996 with the world population being approximately 5.7
billion, an
estimated 2.8 million people had a confirmed diagnosis of IPD.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
2
Current pharmacological treatments for IPD and other Parkinsonian-like motor
disorders include anticholinergic agents, catechol-o-methyltransferase
inhibitors and
dopaminergic agents (Physicians' Desk Reference, 2000, 54"' Ed., Medical
Economics
Company, Inc., Montvale, NJ). Since the late sixties, dopamine precursor L-
DOPA,
has been employed for the symptomatic relief of IPD motor dysfunction (Mena,
M.A.
et al., "Pharmacokinetics of L-DOPA in patients with Parkinson's disease,"
(1986)
Advances in Neurology 45:481-486). However, following long term use of L-DOPA
(generally 5-8 years), diminished therapeutic efficacy is observed in
approximately
50% of IPD patients (Roos, R.A. et al., "Response fluctuations in Parkinson's
disease,"
(1990) Neurology 40(9):1344-1346). A wearing off of L-DOPA efficacy precedes
the
development of serious motor side effects such as on/off motor oscillations
and
dyskinesias (Carlsson, Arvid, "Development of new pharmacological approaches
in
Parkinson's disease," (1986) Advances in Neurology 45:513-518). Further, when
medications are increased to compensate for the development of these new motor
dysfunctions, more serious side effects are generally observed, including
psychiatric
complications, while producing only minimal therapeutic benefit (Stoof, J.C.
et al.,
"Leads for the development of neuroprotective treatment in Parkinson's disease
and
imaging methods for estimating treatment efficacy," (1999) Eur. J. Pharmacol.
375(1-
3):75-86).
Deprenyl, a monoamine oxidase (MAO) B inhibitor, was the first drug
suggested to provide causal treatment of Parkinson's Disease by alleviating
symptoms
and attenuating the progression of the illness (Mytilineou, C. et al., "L-(-)-
desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects
mesencephalic
dopamine neurons from excitotoxicity in vitro," (1997) J. Neurochemistry
68(1):434-
436). However, there remains much controversy regarding the therapeutic
efficacy of
Deprenyl. While some physicians prefer to prescribe Deprenyl when patients
first
present with symptoms of Parkinson's Disease (Goldstein, M. and Lieberman, A.,
"The
role of the regulatory enzymes of catecholamine synthesis in Parkinson's
disease,"
(1992) Neurology 42(54):8-12), other physicians dispute claims of neural
protection
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
(Olanow, C.W. and Calne, D., "Does selegiline monotherapy in Parkinson's
disease act
by symptomatic or protective mechanisms?" (1992) Neurology 42(S4):13-26).
Poewe and Wenning (Poewe, W.H. and Wenning, G.K., "The natural history of
Parkinson's disease," (1998) Annals ofNeurology 44(S1):Sl-S9) reviewed several
longitudinal studies which evaluated Parkinson's Disease medications. The
Parkinson's Research Group of the United Kingdom found that when Deprenyl was
co-
administered with L-DOPA, a 60% increase in patient mortality was observed,
compared to the group being treated with L-DOPA only. Deprenyl is now rarely
prescribed by European physicians for the treatment of IPD. In contrast,
American
researchers determined that Deprenyl is capable of delaying the need to
commence L-
DOPA treatment for a period of up to nine months. However, no neural
protection was
found in two-year patient follow-up examinations (Poewe and Wenning, 1998,
supra).
In Parkinson's Disease the average lifespan is 9.4 years following an initial
diagnosis.
Further, the onset of gait disorders is closely associated with mortality
rate. To be
superior to current causal treatments (i.e- Deprenyl), a pharmacological
treatment must:
a) prolong the need to commence L-DOPA for more than nine months; b) retain
efficacy beyond a two-year period; and, c) prevent, delay, or otherwise
alleviate gait
disorders.
Up to 20% of the people initially diagnosed with IPD, actually suffer from
atypical IPD (APD), striatonigral degeneration (SND), or multiple symptom
atrophy
(MSA) (Antonini, A. et al., "Differential diagnosis of Parkinsonism with
['8F]Fluorodeoxyglucose and PET," (1998) Movement Disorders 13(2):268-274).
Little or no response to conventional Parkinson's Disease drug therapy is
usually the
differentiating factor between a diagnosis of APD, SND and MSA as opposed to
IPD
(Dethy, S. et al., "Asymmetry of basal ganglia glucose metabolism and dopa
responsiveness in Parkinsonism," (1998) Movement Disorders 13(2):275-280).
Often,
little can be done for people suffering these atypical afflictions. Therefore,
it would be
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
4
of great benefit if a pharmacological means were identified that could
alleviate
symptoms of atypical Parkinson's Disease, as well as IPD.
The exact cause or causes of IPD are still unknown. Nonetheless, scientists
have discovered a multitude of pathological abnormalities in the Parkinsonian
brain.
These findings include but are not limited to: a) toxic metabolite formation
during
neuromelanin (NM) synthesis (Graham, D.G., "Autoxidation versus covalent
binding
of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and
related compounds toward C 1300 neuroblastoma cells in vitro" ( 1978)
Molecular
Pharmacology 14:644-653); b) heightened affinity of endogenous and exogenous
toxins for NM (Tipton, K.F. and Singer, T.P., "Advances in our understanding
of the
mechanisms of the neurotoxicity of MPTP and related compounds," (1993) J.
Neurochem. 61(4):1191-1206); c) mitochondria) impairment (Mizuno, Y. et al.,
"Mitochondria) dysfunction in Parkinson's disease," ( 1998) Annals of
Neurology
44(S1):599-S109); d) increased oxidative stress potentiated by reduced levels
of
antioxidants (Merad-Boudia, M. et al., "Mitochondria) impairment as an early
event in
the process of apoptosis induced by glutathione depletion in neuronal cells:
relevance
to Parkinson's disease," (1998) Biochem. Pharmacology 56:645-655); e) protein
oxidation and lipid peroxidation (Jenner, P. et al., "Understanding cell death
in
Parkinson's disease," ( 1998) Annals of Neurology 44( 1 ):572-S84); f)
augmented iron
content and abnormal Fe(II)/Fe(III) ratios (Riederer, P. et al., "Transition
metals,
ferritin, glutathione, and ascorbic acid in Parkinsonian brains," ( 1989) J.
Neurochemistry 52(2):51 S-520); and g) the accumulation of extracellular
protein
peptide fragments (Loo, D.T. et al., "Apoptosis is induced by (3-amyloid in
cultured
central nervous system neurons," (1993) Proc. Natl. Acad. Sci. USA 90:7951-
7955).
An example of these extracellular amyloid peptide fragments are the non-A13
components in Lewy bodies (Culvenor, J.G. et al., "Non-A(3 component of
Alzheimer's
disease amyloid (NAC) revisited," (1999) Am. J. Pathology 155:1173-1181) which
trigger an apoptotic cascade. Taken individually, these pathological findings
would
not pose a tremendous cellular threat. Collectively and occurnng
simultaneously, they
CA 02416233 2003-O1-13
WO 01/03649 PCT/USOO140385
S
serve to progressively annihilate the melanized catecholamine neurons residing
in the
mesencephalon, ultimately producing the classic signs of Parkinson's Disease.
Chloroquine Compounds
Chloroquine [7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline] (The
Merck Index, p. 2220, 1996) is a synthetically manufactured anti-malarial
containing
the quinoline nucleus. Chloroquine was developed over fifty years ago. It
continues to
be the most widely employed drug for the treatment of the asexual erythrocytic
form of
P. falciparum (Deepalakshmi, P.D. et al., "Effect of chloroquine on rat liver
mitochondria," (1994) Indian J. Exp. Biology 32(11):797-799). Unfortunately,
due to
widespread use of chloroquine, treatment resistant stains of malaria, first
reported in
1961, continue to emerge globally, making the use of chloroquine obsolete in
many
regions (Bitonti, A.J. et al., "Reversal of chloroquine resistance in malaria
parasite
plasmodium falciparum by desipramine," (1988) Science 241:1301-1303). A number
of chloroquine derivates have been identified for antimalarial and other use.
See U.S.
Patents 5,948,791, 5,834,505, 5,736,557, 5,639,737, 5,624,938, 5,596,002 and
4,421,920.
Due to the widespread use of chloroquine, a number of beneficial therapeutic
properties and medicinal applications, outside of conventional malarial
treatment, have
been identified. Most of the following studies employed chloroquine phosphate.
Chloroquine phosphate is a potent inhibitor of acid chondromucoprotease
present in cartilage and of cathepsin B l, a protease especially important in
the initiation
ofproteolysis (De Duve, C. et al., "Lysosomotropic agents," (1974) Biochem.
Pharm.
23:2495-2531). These properties have rendered chloroquine phosphate useful in
the
treatment of rheumatoid arthritis (Clinical Toxicolo~y, supra, Section III,
pp. 355-
362). Further, chloroquine phosphate is known to reduce hypertension
(Physician's
Desk Reference, pp. 2301-2302, 1996). Chloroquine phosphate and other 4-
aminoquinoline compounds have been prescribed for the treatment of cardiac
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
6
arrhythmia (Clinical Toxicolo~y, supra, Section III, pp. 355-362). A version
of
antimalarial drug called Cardioquin~ is produced by the Purdue Fredrick
Company for
the maintenance of sinus rhythm after conversions from atrial fibrillation
(Physician's
Desk Reference, pp. 2521-2522, 2000). Chloroquine phosphate also targets
malignant
metastatic melanomas that generally bear an accumulation of melanin. The
utilization
of chloroquine phosphate for the treatment of these tumors is limited by the
lack of
accumulation in the amelanotic forms that readily manifest (Lindquist, N.G.,
"Accumulation of drugs on melanin," (1973) Acta Radiol. Diag. (Stockholm)
325:1-
92). A more recent application of chloroquine phosphate is to suppress the
human
immunodeficiency virus type 1 (HIV-1) replication in vivo within T-cells and
monocytes (Sperber, K. et al., "Hydroxychloroquine treatment of patients with
human
immunodeficiency virus type 1," (1995) Clinical Therapeutics 17(4):622-636;
Ornstein, M.H. and Sperber, K., "The anti-inflammatory and antiviral effects
of
hydroxychloroquine in two patients with acquired immunodeficiency syndrome and
active inflammatory arthritis," (1996) Arthritis Rheum. 39(1):157-161).
The above medicinal applications of chloroquine phosphate are generally known
to those practicing medicine in the USA. The following applications of
chloroquine
phosphate have been discovered and successfully employed by doctors throughout
the
world. Chloroquine phosphate has been used to treat renal disorders such as
glomerulonephritis and amyloidosis, with observed improvement in renal
function and
attainment of various lengths of remission (Makarenko, LE. and Levitsky, E.P.,
"Resoquin in the clinic of internal illnesses, and the possible side effects
of its use,"
(1950). A randomized trial of the prolonged use of chloroquine phosphate to
treat
advanced pulmonary sarcoidosis, suggests that patients responded better to
chloroquine
phosphate and withstood medication side effects better than with conventional
corticosteroids (Baltzan, M. et al., "Randomized trial of prolonged
chloroquine therapy
in advanced pulmonary sarcoidosis," (1999) Am. J. Respir. Crit. Care Med.
160:192-
197). Conditions of acute hypertension can benefit from the administration of
chloroquine phosphate, which acts as a vasodilator without depressing cardiac
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
7
contractibility (Abiose, A.K. et al., "Chloroquine-induced venodilation in
human hand
veins," (1997) Clin. Pharm. c& Therapeutics 61(6):677-683). Chloroquine
phosphate
inhibits lysosomal proteolysis in vitro, and has been suggested to be a useful
agent in
counteracting protein wasting observed in several catabolic diseases (De Feo,
P. et al.,
"Chloroquine reduces whole body proteolysis in humans," ( 1994) Am. J.
Physiology
267:E183-E186). Chloroquine phosphate inhibits the biological availability of
iron and
has been suggested as advantageous for the treatment of iron-loading disorders
(Legssyer, R. et al., "Effect of chronic chloroquine administration on iron
loading in
the liver and reticuloendothelial system and on oxidative responses by the
alveolar
macrophages," (1999) Biochem. Pharmacology 57(8):907-911). Several case
histories
have been published regarding the efficacy in administering chloroquine
phosphate to
infants suffering from desquamative interstitial pneumonitis who presented
with failure
to thrive, tachypnea and hypoxia (Springer, C. et al., "Chloroquine treatment
in
desquamative interstitial pneumonia," ( 1987) Archives of Disease in Childhood
62:76-
77), and were non-respondent to steroids (Leahy, F. et al., "Desquamative
interstitial
pneumonia responsive to chloroquine," (1985) Clinical Pediatrics 24(4):230-
232).
Further recognized, but non-FDA approved, uses of chloroquine phosphate
include treatments for: cholera, idiopathic pulmonary hemosiderosis, lupus
erythematosus, lymphoid interstitial pneumonitis, onchocerca volvulus,
porphyria
cutanea tarda, m. sarcoidosis, and ulcerative colitis (MICROMEXEX~, 2000,
available: http//phamtom.uchsc.edu/mdxcgi/di). U.S. Patent 5,430,039 suggests
the
use of chloroquine to inhibit neuronal cell death resulting from a calcium-
related
disorder of the central or peripheral nervous system, erroneously
characterizing
Parkinson's Disease as such a disorder. Vainshtok, A.B., "Treatment of
Parkinsonism
with delagil," (1972) Klin. Med (Mosk) 50(9):51-56, reports administration of
Delagil,
a chloroquine compound or analog (exact compound unknown) to a group of
medication-free patients (dosage unknown) suffering symptoms related to
Parkinson's
disease with moderate to dramatic response.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
Enantiomers of Chloroquine
Chloroquine and hydroxychloroquine are racemic mixtures of (-)- and (+)-
enantiomers. The (-)-enantiomers are also known as (R)-enantiomers (physical
rotation) and 1-enantiomers (optical rotation). The (+)-enantiomers are also
known as
(S)-enantiomers (physical rotation) and r-enantiomers (optical rotation). The
(+)-
enantiomer metabolizes peripherally about eight times more rapidly than the (-
)
enantiomer, producing toxic metabolites including de-ethyl chloroquine
(Augustijins,
P. and Verbeke, N. [1993] "Stereoselective pharmacokinetic properties of
chloroquine
and de-ethyl chloroquine in humans," Clinical Pharmacokinetics 24(3):259-69;
Augustijins, P. et al. [1999], "Stereoselective de-ethylation of chloroquine
in rat liver
microsomes," Eur. J. Drug Metabolism & Pharmacokinetics 24( 1 ):105-8;
DuCharme,
J. and Farinotti R. [1996], "Clinical pharmacokinetics and metabolism of
chloroquine,"
Clinical Pharmacokinetics 31 (4):257-74). Administering (+)-chloroquine may
cause
cardiac side effects due to toxic metabolite formation. The (-)-enantiomer has
a longer
half life and lower clearance than the (+)-enantiomer (Ducharme, J. et al. [
1995),
"Enantio-selective disposition of hydroxychloroquine after a single oral dose
of the
racemate to healthy subjects," British .I. Clinical Pharmacology 40(2):127-
33). The
enantiomers of chloroquine and hydroxychloroquine may be prepared by
procedures
known to the art.
All publications referred to herein are incorporated by reference to the
extent not
inconsistent herewith.
SUMMARY OF THE INVENTION
This invention provides compositions and methods for increasing cellular
respiration of melanized catecholamine neurons such as dopamine neurons in the
substantia nigra, epinephrine and norepinephrine neurons, of protecting such
neurons
against oxidative degradation, and for treatment of Parkinson's Disease,
including both
alleviation of symptoms and preventing onset or progression of symptoms. The
compositions of this invention may be administered long-term. The compositions
of
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
9
this invention are also useful for preventing on-off syndrome, a condition in
which L-
Dopa and other dopamine agonists temporarily or permanently lose their ability
to
ameliorate the symptoms of Parkinson's Disease after an initial period of
effectiveness.
The term "CQ" includes chloroquine (7-chloro-4-(4-diethylamino-1-
methylbutylamino)quinoline), chloroquine phosphate (7-chloro-4-(4-diethylamino-
1-
methylbutylamino) quinoline phosphate, and hydroxychloroquine (7-chloro-4-(4-
diethylamino-1-methylbutylamino) quinoline), and mixtures thereof. Similarly,
the
terms (-)-chloroquine and (+)-chloroquine include (-)- and (+)-chloroquine
phosphate
and (-)- and (+)-hydroxychloroquine respectively.
Compositions useful for increasing cellular respiration of melanized
catecholine
neurons, and/or alleviating, preventing or halting progress of Parkinson's
symptoms
comprise neuromelanin-binding chloroquine analogs and derivatives containing a
quinoline nucleus, preferably selected from the group consisting of:
7-chloro-4-(4-diethylamino-1-methylbutylamino)quinoline (chloroquine);
7-hydroxy-4-(4-diethylamino-1-methylbutylamino)quinoline;
chloroquine phosphate;
7-chloro-4-(4-diethylamino-1-butylamino)quinoline (desmethylchloroquine);
7-hydroxy-4-(4-diethylamino-1-butylamino)quinoline;
7-chloro-4-( 1-carboxy-4-diethylamino-1-butylamino)quinoline;
7-hydroxy- 4-(1-carboxy-4-diethylamino-1-butylamino)quinoline;
7-chloro-4-( 1-carboxy-4-diethylamino-1-methylbutylamino)quinoline;
7-hydroxy- 4-(1-carboxy-4-diethylamino-1-methylbutylamino)quinoline;
7-chloro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline
(hydroxychloroquine);
7-hydroxy-4-(4-ethyl-(2-hydroxyethyl)-amino-1-methylbutylamino)quinoline;
hydroxychloroquine phosphate;
7-chloro-4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline
(desmethylhydroxychloroquine);
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
7-hydroxy-4-(4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline;
7-chloro-4-( 1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline;
7-hydroxy-4-( 1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-butylamino)quinoline;
7-chloro-4-( 1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-
methylbutylamino)quinoline;
5 7-hydroxy-4-(1-carboxy-4-ethyl-(2-hydroxyethyl)-amino-1-
methylbutylamino)quinoline;
8-[(4-aminopentyl)amino)-6-methoxydihydrochloride quinoline;
1-acetyl-1,2,3,4-tetrahydroquinoline; 8-[4-aminopentyl)amino]-6-
methoxyquinoline
dihydrochloride;
10 1-butyryl-1,2,3,4-tetrahydroquinoline; 7-chloro-2-(o-chlorostyryl)-4-[4-
diethylamino-
1-methylbutyl]aminoquiinoline phosphate;
3-chloro-4-(4-hydroxy-a,a'-bis(2-methyl-1-pyrrolidinyl)-2,5-xylidinoquinoline,
4-[(4-
diethylamino)-1-methylbutyl)amino]-6-methoxyquinoline;
3,4-dihydro-1 (2H)-quinolinecarboxyaldehyde;
1,1'-pentamethylenediquinoleinium diiodide; and 8-quinolinol sulfate,
enantiomers
thereof, complexes thereof with targeting agents, and mixtures thereof, as
well as
suitable pharmaceutical salts thereof. Chloroquine and hydroxychloroquine are
preferred; (-)-enantiomers thereof are more preferred, and complexes thereof
with
targeting agents are most preferred. Neuromelanin-binding compounds such as
chlorpromazine and other antipsychotics which bind to dopamine receptors are
not
included within the scope of PD-effective neuromelanin-binding compounds of
this
invention. Any chloroquine analog or derivative known to the art and capable
of
binding neuromelanin may be useful in the methods of this invention.
Preferably the neuromelanin-binding compound is selected from the group
consisting of compounds capable of crossing the blood-brain barner in
effective
amounts. Such compounds include those which are more lipophilic, are capable
of
changing to effective chirality after crossing the blood-brain barrier, have
side chain
substituents which enhance compound transport via blood-brain barrier
transporter
mechanisms, or are complexed with antibodies or other targeting moieties, or
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
11
administered in combination with other compounds facilitating their crossing
the
blood-brain barrier, as known to the art. The (-)-enantiomer of chloroquine
(referred to
herein as the active enantiomer) is more capable of crossing the blood-brain
barrier
than its stereoisomer and is therefore preferred.
In a preferred embodiment, the compositions useful for increasing cellular
respiration of melanized catecholamine neurons comprise an effective amount of
a
composition comprising (-)-CQ or (-)-CQ complexed with a targeting agent; an
amount
of (+)-CQ less than that of said (-)-CQ or (-)-CQ complexed with a targeting
agent; and
a suitable pharmaceutical carrier.
A targeting agent is a substance that when complexed with the CQ helps carry
it
across the blood brain barrier. Preferred targeting agents are lipophilic
moieties known
to the art which are attached to the active molecule at a position which does
not
interfere with the ability of the quinoline ring to bind to neuromelanin, and
antibodies
such as an antibody capable of binding to the transferrin receptor on brain
capillary
cells, e.g., as described in U.S. Patent No. 6,015,555, incorporated herein by
reference
to the extent not inconsistent herewith.
Such compositions containing (-)-chloroquine may include anywhere from no
(+)-CQ to about 49% (+)-CQ. An amount of (+)-CQ sufficient to bind to enzymes
causing peripheral breakdown of CQ is preferred, leaving more of the (-)-CQ to
cross
the blood brain barner where its therapeutic effect takes place. Preferably
the
compositions comprise between about 10% and about 20% (+)-CQ.
In one embodiment, a single adult dosage amount of said composition effective
for increasing cellular respiration of melanized catecholamine neurons is
provided,
preferably less than an antimalarial single adult dosage amount, more
preferably less
than about 1 mM base equivalent, and most preferably less than about 0.5 mM
base
equivalents of CQ. As is known to the art, the term "base equivalents" refers
to
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00140385
12
amount of active ingredient (e.g., in reference to chloroquine phosphate,
refers to the
chloroquine minus the phosphate and filler components). A single adult dosage
amount with respect to use for alleviation, preventing or stopping progression
of
symptoms of Parkinson's Disease or for other uses will be an amount effective
when
administered daily to provide the stated therapeutic effect.
Compositions of this invention may also comprise an effective amount of at
least one adjuvant selected from the group consisting of antioxidants, retinal
protective
agents, other neural protective compounds, dopamine or dopamine agonists, and
free
radical deactivators. The antioxidant may be any antioxidant known to the art
to
prevent free radical formation and oxidative degradation of tissues and is
preferably
selected from the group consisting of probucol, pyncnogenol, Vitamin C,
Vitamin E,
superoxide dismutase, preferably synthetic, BHT, BHA, and melatonin. The
retinal
protective agent is preferably a composition administered locally to prevent
binding of
retinal melanin with the CQ, as is known to the art, e.g., alkanes and
alcohols of C~-C4,
and ginko biloba. The neural protective compound is any compound known to the
art
and preferably is selected from the group consisting of selegiline
hydrochloride and
other monoamine oxidase inhibitors. The dopamine agonist is any compound known
to the art as an anti-Parkinson's treatment and preferably is selected from
the group
consisting of L-DOPA, pramipexole, ropinerole, bromocriptine, tolcapone, and
carbidopa. The free radical deactivator is any compound known to the art and
preferably is selected from the group consisting of superoxide dismutase,
selegiline,
hydrochloride, and tolcapone.
This invention also provides kits comprising in close proximity, such as in a
container or blister pack, effective dosage amounts and forms of the
compositions of
this invention for single doses, or doses per week, or other appropriate time
period,
preferably in combination with an adjuvant, such as an antioxidant, dopamine
or
dopamine agonist, or other adjuvant as discussed above suitable for co-
administration
with said composition, in effective dosage forms and amounts.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
13
Suitable pharmaceutical carriers are known to the art and include carriers
aiding
in transport across the blood/brain barner, such as nanoparticles onto which
the
compositions are absorbed, coated with a detergent, e.g., as described in
Begley, D.J.
( 1996) "The blood-brain barrier: principles for targeting peptides and drugs
to the
central nervous system," J. Pha~m. Pharmacol. 48(2):136-46, incorporated
herein by
reference to the extent not inconsistent herewith.
This invention also provides methods for increasing cellular respiration of
melanized catecholamine neurons, and methods for alleviating symptoms or
stopping
appearance and/or progression of symptoms of Parkinson's Disease, and methods
for
preventing symptoms of on-off syndrome associated with treatment with dopamine
or a
dopamine agonist of a patient suffering symptoms of a disease selected from
the group
consisting of idiopathic and atypical Parkinson's disease, conditions
characterized by
nigrostriatal degeneration, multiple system atrophy, and vascular Parkinson's
Disease,
said methods comprising administering to said patient an effective amount of
the above
composition of this invention. The methods are suitable for any mammal having
such
melanized neurons or symptoms of Parkinson's Disease. Methods for treating or
preventing symptoms of Parkinson's Disease also comprise identifying patients
having
such symptoms or at risk of developing them.
Further provided are methods of making pharmaceutical compositions effective
for increasing cellular respiration of melanized catecholamine neurons
comprising:
providing a compound or complex of this invention as described above,
providing a
suitable pharmaceutical Garner; and mixing said compound or complex and
pharmaceutical carrier to form a composition effective to increase cellular
respiration
of melanized catecholamine neurons.
Instead of mixing (+)-CQ with (-)-CQ, the method of making the compositions
of this invention comprising (-)-CQ may be practiced by starting with racemic
CA 02416233 2003-O1-13
WO 01/03649 PCT/~JS00/40385
14
chloroquine and removing an amount of (+)-CQ to leave a CQ composition
effective to
increase cellular respiration of melanized catecholamine neurons.
DETAILED DESCRIPTION
The term "increasing cellular respiration" means measurably increasing oxygen
consumption, increasing aerobic cellular respiration and reducing anaerobic
cellular
respiration, e.g., as measured by lactate in the cerebral spinal fluid.
The term "diminishing oxidative degradation of dopamine neurons in the
substantia nig~a" means measurably diminishing such degradation as measured by
assays known to the art, including measures of free iron ion availability and
oxygenated radical formation.
The term "Parkinson's Disease" as used herein includes idiopathic Parkinson's
Disease (IPD), atypical Parkinson's Disease (APD), striatonigral degeneration
(SND),
multiple symptom atrophy (MSA), and vascular Parkinson's Disease.
The term "alleviating symptoms of Parkinson's Disease" means measurably
reducing, inhibiting, attenuating and/or compensating for at least one symptom
of
Parkinson's disease, such as tremor, postural imbalance, rigidity,
bradykinesia,
akinesia, gait disorders, and on/off fluctuations. These symptoms may result
from
toxic metabolite formation during neuromelanin (NM) synthesis, heightened
affinity of
endogenous and exogenous toxins for NM, mitochondrial impairment, increased
oxidative stress potentiated by reduced levels of antioxidants, protein
oxidation and
lipid peroxidation, augmented iron content and abnormal Fe(II)/Fe(III) ratios,
and the
accumulation of extracellular protein peptide fragments, which conditions may
also be
alleviated by the compositions of this invention.
The compositions of this invention containing (-)-CQ should have more (-)-CQ
or (-)-CQ complexed with a targeting agent than (+)-CQ because the toxic
metabolites
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
of (+)-CQ make it less suitable for long-term use, and the better melanin-
binding
properties of (-)-CQ, its longer half life, lower clearance, and better
ability to cross the
blood brain barrier make it more effective for long-term administration (e.g.
at least
about six weeks, more preferably, about two years, and most preferably, at
least about
ten years or more.
An effective amount of the compositions of this invention is an amount
necessary to produce a measurable effect. For example, an effective amount of
the
compositions of this invention to increase cellular respiration measurably
increases
10 cellular respiration by assays known to the art as discussed above. In
compositions
containing (-)-CQ, the effect may be produced by the (-)-CQ, or partially by
the (-)CQ
and partially by (+) CQ. Similarly, an effective amount of a composition of
this
invention to alleviate or stop the progression of symptoms of Parkinson's
Disease is an
amount which does so based on art-known tests such as the Unified Parkinson's
15 Disease Rating Scale and the Tinetti Gait and Balance Assessment Tool,
comparing
symptoms of treated patients with symptoms of the same patients prior to
and/or after
treatment, or with symptoms of untreated patients at the same stage of
Parkinson's
Disease.
Preventing symptoms of Parkinson's Disease includes identifying patients at
risk for developing such symptoms. Identification of patients susceptible to
onset of
Parkinson's Disease may be done by genetic testing, prediction from family
history or
other means known to the art such as PET scans. When symptoms of Parkinson's
do
not develop, or do not develop to the expected (average) degree, they are
considered to
have been prevented by the methods and compositions of this invention.
Preventing on-off symptoms in patients being treated with L-Dopa or like
medications means measurably stopping or decreasing such symptoms as compared
with patients at similar stages of Parkinson's Disease being treated with such
medications.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
16
The compounds of this invention may formulated neat or may be combined with
one or more pharmaceutically acceptable carriers for administration. For
example,
solvents, diluents and the like, and may be administered orally in such forms
as tablets,
capsules, dispersible powders, granules, or suspensions containing, for
example, from
about 0.05 to 5% of suspending agent, syrups containing, for example, from
about 10
to 50% of sugar, and elixirs containing, for example, from about 20 to 50%
ethanol,
and the like, or parenterally in the form of sterile injectable solution or
suspension
containing from about 0.05 to 5% suspending agent in an isotonic medium. Such
pharmaceutical preparations may contain, for example, from about 0.05 up to
about
90% of the active ingredient in combination with the carrier, more usually
between
about 5% and 60% by weight.
The effective dosage of active ingredient employed may vary depending on the
particular mixture employed, the mode of administration and the severity of
the
condition being treated. However, in general, satisfactory results are
obtained when
the compounds of the invention are administered at a daily adult dosage of
from about
0.5 to about 1000 mg, optionally given in divided doses two to four times a
day, or in
sustained release form. For most large mammals the total daily dosage is from
about 1
to 1000 mg, preferably from about 2 to 500 mg. Dosage forms suitable for
internal use
comprise from about 0.5 to 1000 mg of the active compound in intimate
admixture
with a solid or liquid pharmaceutically acceptable carrier. This dosage
regimen may be
adjusted to provide the optimal therapeutic response. For example, several
divided
doses may be administered daily or the dose may be proportionally reduced as
indicated by the exigencies of the therapeutic situation. Preferably a single
daily adult
dose comprises less than about 1 mM, and more preferably less than about 0.5
mM
base equivalents, more preferably less than about 1 mM, and more preferably
less than
about 0.5 mM base equivalents.
The compounds of this invention may be administered orally as well as by
intravenous, intramuscular, or subcutaneous routes. Solid carriers include
starch,
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
17
lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin,
while
liquid Garners include sterile water, polyethylene glycols, non-ionic
surfactants and
edible oils such as corn, peanut and sesame oils, as are appropriate to the
nature of the
active ingredient and the particular form of administration desired. Adjuvants
customarily employed in the preparation of pharmaceutical compositions may be
advantageously included, such as flavoring agents, coloring agents, preserving
agents,
and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.
The preferred pharmaceutical compositions from the standpoint of ease of
preparation and administration are solid compositions, particularly tablets
and hard-
filled or liquid-filled capsules. Oral administration of the compounds is
preferred. In
some cases it may be desirable to administer the compounds to the patient's
airways in
the form of an aerosol.
The compounds of this invention may also be administered parenterally or
intraperitoneally. Solutions or suspensions of these active compounds as a
free base or
pharmacologically acceptable salt can be prepared in water suitably mixed with
a
surfactant such as hydroxy-propylcellulose. Dispersions can also be prepared
in
glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under
ordinary
conditions of storage and use, these preparation contain a preservative to
prevent the
growth of microorganisms.
The pharmaceutical forms suitable for injectable use include sterile aqueous
solutions or dispersions and sterile powders for the extemporaneous
preparation of
sterile injectable solutions or dispersions. In all cases, the form must be
sterile and
must be fluid to the extent that easy syringability exists. It must be stable
under the
conditions of manufacture and storage and must be preserved against the
contaminating
action of microorganisms such as bacteria and fungi. The carrier can be a
solvent or
dispersion medium containing, for example, water, ethanol, polyol (e.g.,
glycerol,
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
18
propylene glycol and liquid polyethylene glycol), suitable mixtures thereof,
and
vegetable oils.
"Suitable pharmaceutical carriers" as referred to herein include distilled and
pharmaceutical grade water but do not include water or buffers unsuitable for
administration to a human patient.
There are several mechanisms by which neuromelanin may contribute to
symptoms of Parkinson's disease by contributing to formation of toxic products
including superoxide and hydroxy radicals, which catalyze lipid peroxidation,
and
oxidation of NADH resulting in disruption of the neuron's respiration and
reducing the
amount of energy available to the neurons via aerobic respiration.
Neuromelanin can be considered a waste product of catecholamine degradation
and gradually accumulates within the cytosol of catecholamine neurons
throughout
one's lifetime. Dopamine is autoxidized to cytotoxic and reactive oxygenated
species
such as 6-hydroxydopamine (6-OHDA) and semiquinone radicals. Low glutathione
levels contribute to oxidative stress in Parkinson's disease, and allow
available
hydrogen peroxide to be further catalyzed by iron into highly toxic superoxide
radicals
and hydroxyl radical species as well as semiquinone radicals. Dopamine and L-
DOPA
interaction with superoxide radicals augments depletion of glutathione,
leading to a
downward spiral of detrimental reactions.
Monoamine oxidase forms toxic metabolites from a number of substances such
as beta-carboline derivatives and tetrahydroisoquinoline which are present in
excessive
amounts in the cerebral spinal fluid of people with Parkinson's Disease. These
toxic
metabolites have high affinity to neuromelanin, and once bound may cause
almost
complete arrest of ATP production, resulting in impaired respiration, loss of
energy
available to the neurons and massive melanized cell loss which leads to
symptoms of
Parkinson's Disease. Inhibitors of monoamine oxidase B such as Deprenyl
prevent
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
19
formation of these toxic metabolites. Iron also tends to bind to neuromelanin,
resulting in a cascade of pathogenic reactions leading to neuronal death.
Increasing
iron concentrations in basal ganglia are observed with normal aging, and in
patients
with Parkinson's Disease, iron is pathologically elevated with high
ferric/ferrous ion
ratios. The ferric ions contribute, with 6-OHDA, to the formation of harmful
superoxide and hydroxyl radicals leading to lipid peroxidation and cell
breakdown.
Iron chelators have been shown to reverse impaired mitochondrial respiration
caused by 6-OHDA inhibition of NADH dehydrogenase. 6-OHDA catalyzes the
release of iron from intracellular ferritin stores which in turn catalyzes
lipid
peroxidation. This toxic chain of events can be inhibited by superoxide
dismutase.
Both iron chelators and chloroquine phosphate have been found to limit the
availability
of free iron, so that it is not available to catalyze these toxic reactions.
The iron transporter protein, diferric transferrin, which delivers iron
throughout
the body also contributes to loss of energy available to the neurons by
interfering with
availability of reduced NADH. Chloroquine phosphate has been found to inhibit
intracellular oxidation of NADH by melanin.
Chloroquine phosphate binds to neuromelanin and does not inhibit enzymatic
synthesis of iron into biologically essential compounds. It not only prevents
incorporation of iron into neurons, but also inhibits and release of iron from
intracellular iron pools. In addition chloroquine phosphate has been found to
heighten
an astrocytic immune response against accumulation of extracellular protein
deposits in
the brain contributing to Alzheimer's Disease.
The (-) isomer of chloroquine is an even more effective neuromelanin binder
than racemic chloroquine because it breaks down less peripherally, has a
longer half
life and lower clearance, and so is more available to cross the blood brain
barrier, as
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
well as having a stabilizing effect on DNA. It is therefore preferred for use
in this
invention.
EXAMPLES
Example 1. Enantiomers of chloroquine phosphate were isolated according to the
procedure of Stalcup, A.M. et al. (1996), Analytical Chemistry 68:2248-50.
Comparisons of these enantiomers with respect to ability to inhibit diamine
oxidase and
bind to neuromelanin are performed in vitro. Results show significantly
enhanced
ability of the active enantiomer in both assays to inhibit diamine oxidase and
bind
neuromelanin.
Example 2. A within-subjects, open labeled, parallel study is performed to
evaluate
the efficacy of CQ and enantiomeric CQ (test compounds) for the treatment of
motor
disorders in adults having a diagnosis of Idiopathic Parkinson's Disease (IPD)
and
Symptomatic Parkinson's Disorders, using the Unified Parkinson's Disease
Rating
Scale and the Tinetti Gait and Balance Assessment Tool for assessment pre-
treatment,
during treatment, and two weeks post-treatment. The treatment period assesses
the
safety and durability of response for up to eight weeks. An initial two-week
pre-
treatment period establishes each participant's baseline neurophysiological
and well-
being measures. A final evaluation, administered following a two-week
treatment
withdrawal period, evaluates each participant for symptom restoration.
Thirty adults 30-75 years of age, including fifteen subjects having a
confirmed
diagnosis of stage I-III IPD, designated Group I, and 15 subjects having a
diagnosis of
Symptomatic Parkinson's Disorders resultant from vascular disorders, mufti-
infarct
state, hypoxia, normal pressure hydrocephalus and/or postencephalitis,
designated
Group II, receive a reverse titration of the test medication during the first
week of
treatment. This is followed by a one-time-per-day maintenance dose of 155 mg
per
day taken with the evening meal.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
21
During the initial 24-hour treatment period, subjects are instructed to take
155
mg of the test medication four times per day. On study days 2 and 3, subjects
are
instructed to take 155 mg of test medication 3 times per day. On study days 4,
5 and 6,
subjects are instructed to take 155 mg of test medication 2 times per day. On
study day
S 7, subjects are instructed to take 155 mg of the test medication daily with
their final
meal of the day. On treatment day 10, physicians determine final maintenance
dose to
be taken each evening with the subject's final meal of the day for the
duration of the
treatment period. The maintenance dose may be kept at 155 mg test medication
per
day or adjusted to a lower or higher dose, e.g. down to 100 mg if the subject
is showing
improvement but having gastrointestinal or other discomforts. The dose is
increased
up to 200 mg or 255 mg per day if the subject has not experienced symptom
relief.
Improvements in pre-treatment (baseline) scores on the above-described or
similar measuring instruments, and/or decline in function and score values
following
the medication withdrawal period are used for assessment. Subjects are checked
for
the occurrence of adverse events during the study three times per week.
Laboratory
evaluations (chemistry and hematology profiles) are performed at pre-treatment
screening and during the treatment period on days 10, 28 and 56, and also
during the
two-week post-treatment exit evaluation.
Pre-treatment (baseline) measurements are taken on three separate occasions,
at
three different times of the day, morning, noon and evening, during the
initial two-
week pre-treatment evaluation period. The pre-treatment scores are averaged to
determine each patient's baseline neurophysiological and well-being
measurements.
Five separate neurophysiological and well-being evaluations are administered
on
treatment days 7, 14, 28, 42 and 56. Medication is discontinued immediately
after the
neurophysiological and well-being evaluation administered on treatment day 56.
Patients are seen for one additional exit interview including complete
neurophysiological, well-being, and laboratory evaluations two weeks after the
experimental treatment is discontinued.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
22
Baseline (averaged scores) obtained during the two-week pre-treatment period
are compared to scores obtained during treatment days 7, 14, 28, 42 and 56 to
determine any changes in patient status throughout the treatment period. The
final two-
week post-treatment evaluation scores are used to determine a lingering of
effect by
comparing the two week post-treatment evaluation scores to the pre-treatment
baseline
measurements. Improvement of motor symptoms from pre-treatment, during
treatment
and post-treatment are evaluated, as well as improved well-being. Within-group
improvement scores are analyzed using a t-test of differences for scores from
the pre-
test condition to the post-test condition using a p value of 0.05. Variables
are
summarized by treatment group according to subgroups of gender, race, and age.
Treatment groups are further compared using the Cochran-Mantel-Haenszel test
with
stratifications by the above variables.
Changes from pre-treatment evaluations to days 7, 14, 28, 42 and 56 in each
clinical sign and symptom are summarized by treatment group. The two treatment
groups are compared with respect to the percentage of subjects who showed
either
resolution or improvement in the signs and symptoms among the subjects
presenting
with the signs and symptoms using Fisher's exact test. Potentially clinically
significant
laboratory values and mean changes from baseline of vital signs data are
summarized
within both treatment groups. Times to resolution/improvement of symptoms
after
treatment are also summarized by treatment group and compared using the log
rank
test. Subject satisfaction data and subject symptoms collected from
questionnaires are
also summarized by treatment group and analyzed. Based on an adverse event
rate of
3%, the treatment group sizes used provide approximately 80% power to detect
significance difference at the 0.05 (two-tailed) significance level.
Significant improvement in symptoms and halting of progression of symptoms
both during and post-treatment is observed.
CA 02416233 2003-O1-13
WO 01/03649 PCT/US00/40385
23
While the invention has been described in specific terms, it is not to be
limited
to the description but is to be afforded the full scope of the appended claims
and all
equivalents thereto. For example, other neuromelanin-binding compounds and
complexes containing the quinoline ring structure known to the art are
equivalent to
S those specifically described, as are other modifications to the compositions
to enhance
crossing the blood/brain barrier, biological half life, or other desirable
properties.
